WallStSmart

GE HealthCare Technologies Inc. (GEHC)vsIntelligent Bio Solutions Inc. (INBS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

GE HealthCare Technologies Inc. generates 575808% more annual revenue ($20.63B vs $3.58M). GEHC leads profitability with a 10.1% profit margin vs 0.0%. GEHC earns a higher WallStSmart Score of 60/100 (C+).

GEHC

Buy

60

out of 100

Grade: C+

Growth: 4.0Profit: 7.0Value: 7.3Quality: 4.3
Piotroski: 2/9Altman Z: 1.34

INBS

Hold

40

out of 100

Grade: D

Growth: 6.3Profit: 2.5Value: 5.0Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

GEHCSignificantly Overvalued (-156.0%)

Margin of Safety

-156.0%

Fair Value

$30.94

Current Price

$72.20

$41.26 premium

UndervaluedFair: $30.94Overvalued

Intrinsic value data unavailable for INBS.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

GEHC2 strengths · Avg: 8.5/10
Return on EquityProfitability
22.4%9/10

Every $100 of equity generates 22 in profit

P/E RatioValuation
15.6x8/10

Attractively priced relative to earnings

INBS2 strengths · Avg: 10.0/10
Price/BookValuation
0.4x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
47.6%10/10

Revenue surging 47.6% year-over-year

Areas to Watch

GEHC4 concerns · Avg: 2.8/10
PEG RatioValuation
1.704/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

EPS GrowthGrowth
-17.7%2/10

Earnings declined 17.7%

Altman Z-ScoreHealth
1.342/10

Distress zone — elevated risk

INBS4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$5.50M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Return on EquityProfitability
-1.5%2/10

ROE of -1.5% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : GEHC

The strongest argument for GEHC centers on Return on Equity, P/E Ratio.

Bull Case : INBS

The strongest argument for INBS centers on Price/Book, Revenue Growth. Revenue growth of 47.6% demonstrates continued momentum.

Bear Case : GEHC

The primary concerns for GEHC are PEG Ratio, Piotroski F-Score, EPS Growth.

Bear Case : INBS

The primary concerns for INBS are EPS Growth, Market Cap, Profit Margin.

Key Dynamics to Monitor

GEHC profiles as a value stock while INBS is a hypergrowth play — different risk/reward profiles.

INBS carries more volatility with a beta of 4.63 — expect wider price swings.

INBS is growing revenue faster at 47.6% — sustainability is the question.

GEHC generates stronger free cash flow (917M), providing more financial flexibility.

Bottom Line

GEHC scores higher overall (60/100 vs 40/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

GE HealthCare Technologies Inc.

HEALTHCARE · MEDICAL DEVICES · USA

GE HealthCare Technologies Inc. provides medical technology, pharmaceutical diagnostics, and digital solutions in the United States. The company is headquartered in Chicago, Illinois.

Intelligent Bio Solutions Inc.

HEALTHCARE · MEDICAL DEVICES · USA

Intelligent Bio Solutions Inc. (INBS) is a forward-thinking biotechnology company committed to revolutionizing healthcare through the development of innovative diagnostic solutions and biomarker-driven technologies, especially in the realm of drug abuse testing and monitoring. Leveraging cutting-edge scientific advancements, the company aims to enhance healthcare outcomes by offering highly accurate and rapid-testing methodologies that facilitate timely clinical decision-making. Positioned strategically at the nexus of technology and healthcare, INBS is well-positioned to capitalize on the growing demand for advanced diagnostic tools in a dynamic market landscape.

Want to dig deeper into these stocks?